Business Standard

Monday, December 23, 2024 | 03:56 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Dr Reddy's sells US rights of branded neurology products to Upsher-Smith

The closing of the transaction is subject to various customary closing conditions including antitrust review under Hart-Scott-Rodino Act of the US government

pharma
Premium

Tosymra and Zembrace were designed and developed with the goal of addressing unmet needs of large but discrete segments of patients suffering from episodic migraine

BS Reporter Hyderabad
Dr Reddy's Laboratories Limited announced on Friday that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, pursuant to which the company would sell its US and select territory rights for Zembrace Symtouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray). Earlier these products were commercialised through Dr Reddys' wholly owned subsidiary Promius Pharma.

"Under the agreement, Dr Reddy's will receive $70 million as up-front consideration, $ 40.5 million in near-term milestones and additional financial considerations including, existing contractual obligation and inventory. Subsequently Dr Reddy's will receive sales based royalties on a quarterly basis," the company said. 

The

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in